Akeso says Phase 3 HARMONi-6 overall survival data for ivonescimab in first-line squamous NSCLC lands ASCO plenary slot

PUBT·05/26/2026 04:36:03

Listen to the news

Akeso flagged Phase 3 overall survival results from HARMONi-6 for ivonescimab with chemotherapy in first-line advanced squamous NSCLC.
Results have not yet been presented; ASCO 2026 selected the dataset for the Plenary Session on May 31.
The readout shows a survival advantage for ivonescimab with chemotherapy versus tislelizumab with chemotherapy, supporting differentiation in a key lung cancer setting.
Additional ivonescimab and cadonilimab studies across solid tumors are scheduled for ASCO 2026 presentations, extending visibility for its bispecific antibody portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260035PR_NEWS_USPR_____CN67517) on May 26, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English